Intellia Therapeutics, Inc. beat EPS estimates 81% of the time across 16 reported quarters (13 beats, 3 misses), averaging +5.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.80 | $-0.80 | +0.0% | Beat | Q2 FY26 call · transcript |
| Q1 FY26 | $-0.92 | $-0.81 | +12.0% | Beat | |
| Q4 FY25 | $-0.99 | $-0.83 | +16.2% | Beat | Q4 FY25 call · transcript |
| Q3 FY25 | $-1.02 | $-0.92 | +9.8% | Beat | |
| Q2 FY25 | $-1.03 | $-0.99 | +3.9% | Beat | |
| Q1 FY25 | $-1.26 | $-1.10 | +12.7% | Beat | |
| Q4 FY24 | $-1.32 | $-1.24 | +6.1% | Beat | |
| Q3 FY24 | $-1.37 | $-1.34 | +2.2% | Beat | |
| Q2 FY24 | $-1.21 | $-1.31 | -8.3% | Miss | |
| Q1 FY24 | $-1.35 | $-1.06 | +21.5% | Beat | |
| Q4 FY23 | $-1.47 | $-1.46 | +0.7% | Beat | |
| Q3 FY23 | $-1.52 | $-1.38 | +9.2% | Beat |
Back to NTLA overview · NTLA holders · NTLA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.